FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Alendronate Sodium Tablets USP
Status: Discontinuation
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Mylan Pharmaceuticals Inc. (New 12/01/2016)

Company Contact Information:
800-796-9526

Presentation Posting Date Related Information
Alendronate Sodium Tablets USP, 70 mg , 4s, (NDC 0378-3569-99) 12/01/2016 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety or efficacy.
Alendronate Sodium Tablets USP, 35 mg , 4s, (NDC 0378-3568-99) 12/01/2016 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety or efficacy.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English